Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM54 plus pembrolizumab in previously treated advanced malignancies
2025-523774-16-00Phase 2Authorised
- Sponsor
- PharmaMar
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of PM54 and pembrolizumab in cancer, sponsored by PharmaMar. Primary endpoints: Treatment-emergent adverse events and dose selection and Dose-limiting toxicities in Part 1. Planned start Jun 2026; status: authorised.
02
Drugs
PM54pembrolizumab
03
Conditions
cancer
Beyond the preview
Go deeper on 2025-523774-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523774-16-00.